Cardiotoxicity due to tumoricidal drug use is defined as 
an asymptomatic reduction in Left Ventricular (LV) Ejection 
Fraction (EF) of ≥10% to <55% or as a reduction of the LVEF of 
≥5% to <55% with symptoms of Heart Failure (HF). The 
implementation in routine practices the highly tumoricidal 
anthracycline drugs, taxanes, and trastuzumab cause progressive 
LV dysfunction and symptomatic HF in dose-dependent manner. 
Despite there is potent reversibility of tumoricidal drug-induced 
cardiotoxicity, this adverse effect frequently consists continuously 
and might lead to limited response to medical treatment and 
worse survival sufficiently. The aim of the mini review is 
consideration the clinical evidence that supports the use of cardiac 
biomarkers for early detection of cardiotoxicity. The review is 
reported that the identification of cancer patient with increased 
risk of early cardiotoxicity would allow not only prevention and 
diagnosis of chemotherapy related cardiotoxicity but also 
administration of optimal dose and duration of chemotherapy. 
The predictive role of brain natriuretic peptides, cardiac troponins 
and inflammatory biomarkers (C-reactive protein) is discussed.